Autobahn Therapeutics today announced positive topline results from a first-in-human Phase 1 clinical study assessing the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of escalating doses of ABX-002 in healthy volunteers.
Autobahn Therapeutics today announced positive topline results from a first-in-human Phase 1 clinical study assessing the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of escalating doses of ABX-002 in healthy volunteers.